FinscoFinsco

Amneal Pharmaceuticals (US.AMRX)

Capital Allocation Audit · Period: 2016 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AMRX · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion401.0%↑
ROE363.1%→
Cash Conversion-40.0%↓
D/E Ratio84.54→
Gross Margin43.1%↑
US.AMRX (Amneal Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   401.0%    ↑
ROE              363.1%    →
Cash Conversion  -40.0%    ↓
D/E Ratio         84.54    →
Gross Margin      43.1%    ↑
Key Metrics
US.AMRX (Amneal Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 401.0% ↑
ROE 363.1% →
Cash Conversion -40.0% ↓
D/E Ratio 84.54 →
Gross Margin 43.1% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies